Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas

References

• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–3785.
   PubMed Web of Science ®Google Scholar
• Rahbar Z, Li S, Tavallaee M, et al. Variability in the expression of immunohistochemical markers: implications for biomarker interpretation in cutaneous T-Cell lymphoma. J Invest Dermatol. 2018;138(5):1204–1206.
   PubMed Web of Science ®Google Scholar
• Kim YH, Prince HM, Whittaker S, et al. Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: an ALCANZA Sub-analysis. Eur J Cancer. 2021;148:411–421.
   PubMed Web of Science ®Google Scholar
• Kampa F, Mitteldorf C. A review of CD30 expression in cutaneous neoplasms. J Cutan Pathol. 2021;48(4):495–510.
   PubMed Web of Science ®Google Scholar
• Cyrenne BM, Subtil A, Girardi M, et al. Primary cutaneous aggressive epidermotropic cytotoxic CD8 + T-cell lymphoma: long-term remission after brentuximab vedotin. Int J Dermatol. 2017;56(12):1448–1450.
   PubMed Web of Science ®Google Scholar
• Wehkamp U, Mitteldorf C, Stendel S, et al. Most rare subtypes of cutaneous lymphoma display variable CD30 expression: analysis of the German cutaneous lymphoma network. Br J Dermatol. 2021;185(1):228–230.
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Prince HM, Vermeer MH, et al. Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and sézary syndrome: effect of specific prognostic markers on ­survival and development of a prognostic model. J Clin Oncol. 2015;33(32):3766–3773.
   PubMed Web of Science ®Google Scholar
• Melchers RC, Willemze R, Vermaat JSP, et al. Outcomes of rare patients with a primary cutaneous CD30+ lymphoproliferative disorder developing extracutaneous disease. Blood. 2020;135(10):769–773.
   PubMed Web of Science ®Google Scholar
• Franceschi J, Ehret M, Visseaux L, et al. Survival and prognostic factors in patients with aggressive cutaneous T-cell lymphomas. Acta Derm Venereol. 2022;102:adv00676.
   PubMed Web of Science ®Google Scholar
• [International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–4130.
   PubMed Web of Science ®Google Scholar
• Shustov A, Cabrera ME, Civallero M, et al. ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the international T-cell project. Blood Adv. 2021;5(3):640–648.
   PubMed Web of Science ®Google Scholar
• Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118(15):4024–4035.
   PubMed Web of Science ®Google Scholar
• Willemze R, Hodak E, Zinzani PL, et al. Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv30–iv40.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• d‘Amore F, Gaulard P, Trümper L, et al. Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v108–v115.
   PubMed Web of Science ®Google Scholar
• Fierro MT, Quaglino P, Savoia P, et al. Systemic poly chemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP. Leuk Lymphoma. 1998;31(5–6):583–588.
   PubMed Web of Science ®Google Scholar
• Akpek G, Koh HK, Bogen S, et al. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer. 1999;86(7):1368–1376.
   PubMed Web of Science ®Google Scholar
• Hughes CFM, Khot A, McCormack C, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood. 2015;125(1):71–81.
   PubMed Web of Science ®Google Scholar
• Hanel W, Briski R, Ross CW, et al. A retrospective comparative outcome analysis following systemic therapy in M ycosis fungoides and S ezary syndrome. Am J Hematol. 2016;91(12):E491–E495.
   PubMed Web of Science ®Google Scholar
• Quaglino P, Maule M, Prince HM, et al. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the cutaneous lymphoma international consortium. Ann Oncol. 2017;28(10):2517–2525.
   PubMed Web of Science ®Google Scholar
• Duvic M, Reddy SA, Pinter-Brown L, et al. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res. 2009;15(19):6217–6224.
   PubMed Web of Science ®Google Scholar
• Duvic M, Tetzlaff MT, Gangar P, et al. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33(32):3759–3765.
   PubMed Web of Science ®Google Scholar
• Kim YH, Tavallaee M, Sundram U, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015;33(32):50–58.
   Web of Science ®Google Scholar
• Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555–566.
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Scarisbrick JJ, Dummer R, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021;5(23):5098–5106.
   PubMed Web of Science ®Google Scholar
• Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229–240.
   PubMed Web of Science ®Google Scholar
• Horwitz S, O'Connor OA, Pro B, et al. The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33(3):288–298.
   PubMed Web of Science ®Google Scholar
• Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and sézary syndrome: a proposal of the international society for cutaneous lymphomas (ISCL) and the cutaneous lymphoma task force of the european organization of research and treatment of cancer (EORTC). Blood. 2007;110(6):1713–1722.
   PubMed Web of Science ®Google Scholar
• Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the international society for cutaneous lymphomas (ISCL) and the cutaneous lymphoma task force of the european organization of research and treatment of cancer (EORTC). Blood. 2007;110(2):479–484.
   PubMed Web of Science ®Google Scholar
• Campo E, Jaffe ES, Cook JR, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140(11):1229–1253. blood.2022015851.
   PubMed Web of Science ®Google Scholar
• Salhany KE, Cousar JB, Greer JP, et al. Transformation of Cutaneous T cell lymphoma to large cell lymphoma. Am J Pathol. 1988;1:13.
   Google Scholar
• Willemze R. Spectrum of primary cutaneous CD30 (Ki-l) -positive lymphoproliferative disorders. J Am Acad Dermatol. 1993;28:8.
   Web of Science ®Google Scholar
• Feldman AL, Dogan A, Smith DI, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood. 2011;117(3):915–919.
   PubMed Web of Science ®Google Scholar
• Benton EC, Crichton S, Talpur R, et al. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer. 2013;49(13):2859–2868.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Whittaker S, Willemze R, et al. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood. 2021;2021:12057.
   Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE). 2017.
   Google Scholar
• Feng X, Guo W, Wang Y, et al. The short-term efficacy and safety of brentuximab vedotin plus cyclophosphamide, Epirubicin and prednisone in untreated PTCL: a real-world, retrospective study. Adv Ther. 2022;39(1):532–543.
   PubMed Web of Science ®Google Scholar
• Dumont M, Peffault de Latour R, Ram-Wolff C, et al. Allogeneic hematopoietic stem cell transplantation in cutaneous T-Cell lymphomas. Cancers. 2020;12(10):2856.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Horwitz SM, Advani R, et al. Role of stem cell transplant in CD30-positive PTCL following frontline brentuximab vedotin + CHP or CHOP in ECHELON-2. Blood Adv. 2022; 2020:e003971.
   Google Scholar
• Yu JB, Blitzblau RC, Decker RH, et al. Analysis of primary CD30+ cutaneous lymphoproliferative disease and survival from the surveillance, epidemiology, and end results database. J Clin Oncol. 2008;26(9):1483–1488.
   PubMed Web of Science ®Google Scholar
• Woo DK, Jones CR, Vanoli-Storz MN, et al. Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. Arch Dermatol. 2009;145:74. 10.1001/archdermatol.2009.74.
   Google Scholar